Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
Inactivation or attenuation; producing viral subunits (Class 435/236)
Recovery or purification (Class 435/239)
  • Synthetic Adeno-Associated Virus Inverted Terminal Repeats
    Publication number: 20140271551
    Abstract: This invention relates to synthetic adeno-associated virus (AAV) inverted terminal repeats (ITRs) that exhibit altered activities compared to a naturally occurring AAV ITR and methods of using the same for delivery of nucleic acids to a cell or a subject. The synthetic ITRs provide a larger packaging capacity and the ability to manipulate activities such as transduction efficiency, cellular response to transduction, and transcription.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: MATTHEW LOUIS HIRSCH, RICHARD JUDE SAMULSKI
  • THERAPEUTIC CANCER VACCINE TARGETED TO HAAH (ASPARTYL-[ASPARAGINYL]-BETA-HYDROXYLASE)
    Publication number: 20140271691
    Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-?-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
    Type: Application
    Filed: November 6, 2013
    Publication date: September 18, 2014
    Applicant: PANACEA PHARMACEUTICALS
    Inventors: Biswajit Biswas, Carl R. Merril, Hossein A. Ghanbari
  • PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS, COMPOSITIONS, VACCINE AND METHODS OF USE
    Publication number: 20140271698
    Abstract: The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Dianna M. Murphy JORDAN, Brian Thomas MARTINSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • Newcastle Disease Viruses and Uses Thereof
    Publication number: 20140271677
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
  • PRODUCTION OF AVIAN EMBRYO CELLS
    Publication number: 20140255447
    Abstract: The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 11, 2014
    Applicant: BIOMUNE COMPANY
    Inventors: SHARAD DEVIDASRAO SAWARKAR, CHRISTOPHER PATRICK GULLY
  • VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME
    Publication number: 20140255439
    Abstract: An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided.
    Type: Application
    Filed: May 1, 2012
    Publication date: September 11, 2014
    Applicant: FOLIA BIOTECH INC.
    Inventors: Denis Leclerc, Pierre Savard
  • NOVEL EUROPEAN PRRSV STRAIN
    Publication number: 20140255442
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Kim BURGARD, Jeremy KROLL, Sarah M. LAYTON, Volker OHLINGER, Francois-Xavier ORVEILLON, Stefan PESCH, Michael Dennis PIONTKOWSKI, Michael B. ROOF, Philip UTLEY, Eric Martin VAUGHN
  • Chimaeric protein
    Patent number: 8828407
    Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: September 9, 2014
    Assignee: The Pirbright Institute
    Inventors: Paul Britton, Erica Bickerton, Maria Armesto
  • Influenza viruses and uses thereof
    Patent number: 8828406
    Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: September 9, 2014
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
  • PEPTIDES THAT TARGET DORSAL ROOT GANGLION NEURONS
    Publication number: 20140248334
    Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
    Type: Application
    Filed: February 7, 2014
    Publication date: September 4, 2014
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
  • BRUCELLA PHAGE POLYNUCLEOTIDES AND USES THEREOF
    Publication number: 20140248607
    Abstract: An isolated polynucleotide is disclosed which comprises a nucleic acid sequence of a Brucella phage, the nucleic acid sequence being specific to the Brucella phage and comprising a sequence selected from the group consisting of SEQ ID NOs: 387-393. An exemplary polynucleotide sequence is one which comprises at least 100 consecutive nucleotides of a nucleic acid sequence as set forth in SEQ ID NO: 396. Uses of such sequences are further disclosed.
    Type: Application
    Filed: May 11, 2014
    Publication date: September 4, 2014
    Applicant: The State of Israel, Ministry of Agriculture & Rural Development, Kimron Veterinary Institute
    Inventors: Menachem BANAI, Valeria Strada, Svetlana Bardenstein, Itzhak Ben-Asouli, Farhat Osman
  • VIRUS-LIKE PARTICLES FOR TREATMENT OF VIRAL INFECTIONS
    Publication number: 20140248243
    Abstract: The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.
    Type: Application
    Filed: April 5, 2012
    Publication date: September 4, 2014
    Applicant: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventors: Leslie Lobel, Guy Gubi
  • Immunogenic compositions and methods
    Patent number: 8821885
    Abstract: The invention is directed to immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: September 2, 2014
    Assignee: Longhorn Vaccines & Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Method of targeted gene delivery using viral vectors
    Patent number: 8821856
    Abstract: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: September 2, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Pin Wang, Lili Yang
  • Methods for isolating phage and for controlling microorganism populations with the phage
    Patent number: 8821855
    Abstract: A lytic virus specific for a target strain of a microorganism and substantially free of undesirable genes may be utilized in processes including control of populations of microorganisms. The virus may include a host-range mutant, or “h-mutant.” A method for generating virus includes growing virus-resistant variants of a target strain of a microorganism in the presence of viruses that are specific for the target strain. Only h-mutant viruses will proliferate. Wild-type virus-resistant and virus-resistant variants of a microorganism are also disclosed, as are methods generating such variants. Methods for controlling target strain microorganisms include introducing virus into a treatment site where control of a population of a target strain microorganism is desired or introducing virus-resistant variants of a microorganism into treatment sites where the presence of the microorganism is desired.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: September 2, 2014
    Assignee: Omnilytics, Inc
    Inventors: Lee E. Jackson, Rex S. Spendlove
  • cDNA CONSTRUCT OF SALMONIDAE ALPHAVIRUS
    Publication number: 20140242114
    Abstract: The invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNAs are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines.
    Type: Application
    Filed: October 18, 2013
    Publication date: August 28, 2014
    Inventors: Monique Leberre, Coralie Moriette, Michel Bremont
  • INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
    Publication number: 20140242102
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 28, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Chin-Fen YANG, George KEMBLE, Chongguang LIU
  • Modified Bacteriophage Including an Alpha/Beta Small Acid-Soluble Spore Protein (SASP) Gene
    Publication number: 20140242032
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 28, 2014
    Applicant: PHICO THERAPEUTICS LTD.
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION
    Publication number: 20140242670
    Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: Crucell Holland B.V.
    Inventor: John A. Lewis
  • COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES
    Publication number: 20140243348
    Abstract: Compositions and methods that are useful for the treatment of herpesvirus infection (including herpes simplex virii) are disclosed. Methods for identifying compounds useful for the treatment of herpesvirus infection are also disclosed.
    Type: Application
    Filed: January 22, 2014
    Publication date: August 28, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: David M. Knipe, Kevin Bryant, David H. Dreyfus
  • COMPOSITION
    Publication number: 20140242103
    Abstract: The present invention provides a modified influenza virus wherein the RNA of the haemagglutinin gene has been modified such that the haemagglutinin signal sequence is not expressed and the virus produces a haemagglutinin protein that lacks a functional signal sequence. The invention further provides composition comprising the modified virus and uses of the modified virus.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 28, 2014
    Applicant: ISIS INNOVATION, LTD.
    Inventor: Alain Townsend
  • Cell Line for Production of Adeno-associated Virus
    Publication number: 20140242671
    Abstract: This invention relates to a HEK293 cell line that grows under animal component-free suspension conditions. The cell line is ideal for rapid and scalable production of adeno-associated virus (AAV) and supports production of all serotypes and chimera of AAV.
    Type: Application
    Filed: October 26, 2012
    Publication date: August 28, 2014
    Inventors: Joshua Grieger, Richard Jude Samulski
  • GENE THERAPY VECTORS AND CYTOSINE DEAMINASES
    Publication number: 20140242033
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Application
    Filed: May 9, 2014
    Publication date: August 28, 2014
    Applicant: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Modified virus
    Patent number: 8815563
    Abstract: Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.
    Type: Grant
    Filed: July 18, 2005
    Date of Patent: August 26, 2014
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Benjamin Guy Davis, Leonard William Seymour, Kerry Fisher
  • Method for production of pH stable enveloped viruses
    Patent number: 8815252
    Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: August 26, 2014
    Assignee: Baxter Healthcare SA
    Inventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
  • Viruses Lacking Epithelial Cell Receptor Entry
    Publication number: 20140234943
    Abstract: The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients. Specifically, the document provides nucleic acid molecules encoding viral hemagglutinin (H) polypeptides, viral H polypeptides, and viruses containing nucleic acids and/or H polypeptides. Such viruses are useful for vaccinations and for treating cancer patients as the viruses are not shed.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 21, 2014
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Roberto Cattaneo, Vincent H.J. Leonard
  • Directed Evolution and In Vitro Panning of Virus Vectors
    Publication number: 20140234274
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Application
    Filed: January 17, 2014
    Publication date: August 21, 2014
    Applicant: University of North Carolina at Chapel Hill
    Inventors: Xiao Xiao, Lin Yang
  • PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE
    Publication number: 20140234354
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 21, 2014
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
  • NEWCASTLE DISEASE VIRUS VECTORED AVIAN VACCINES
    Publication number: 20140234358
    Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 21, 2014
    Applicant: MERIAL LIMITED
    Inventors: Michel Bublot, Frederic REYNARD, François-Xavier LE GROS
  • INFECTIOUS CLONES OF TORQUE TENO VIRUS
    Publication number: 20140234355
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.
    Type: Application
    Filed: December 19, 2013
    Publication date: August 21, 2014
    Applicant: Zoetis LLC
    Inventors: Gregory Paul NITZEL, Robert Gerard Ankenbauer, Jay Gregory Calvert, Donna Steuerwald Dunyak, Jacqueline Gayle Marx, Nancee Lois Oien, Douglas Steven Pearce, Mira Ivanova Stoeva, James Richard Thompson
  • Neurovirulent Strain of the West Nile Virus and Uses Thereof
    Publication number: 20140237631
    Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicants: KIMRON VETERINARY INSTITUTE, INSTITUT PASTEUR
    Inventors: Despres Philippe, Vincent Deubel, Jean-Louis Guenet, Marie-Therese Drouet, Mertyn Malkinson, Caroline Banet, Marie-Pascale Frenkiel, Marie-Pierre Courageot, Fasseli Coulibaly, Adeline Catteau, Marie Flamand, Patrick Weber, Pierre-Emmanuel Ceccaldi
  • Novel Nylanderia Fulva Virus
    Publication number: 20140234262
    Abstract: At least one novel virus capable of infecting crazy ants (Nylanderia fulva) is isolated, along with polynucleotide sequences and amino acid sequences of the virus. The virus is capable of be used as a biopesticide to control populations of crazy ants.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 21, 2014
    Inventors: Steven M. Valles, David H. Oi
  • Oncolytic Viruses and Methods for Treating Neoplastic Disorders
    Publication number: 20140234257
    Abstract: The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.
    Type: Application
    Filed: January 28, 2014
    Publication date: August 21, 2014
    Applicant: The Governors of the University of Alberta
    Inventors: David H. Evans, Don B. Gammon
  • Herpes simplex virus vaccines
    Patent number: 8809047
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: August 19, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Feng Yao
  • RECOMBINANT INFLUENZA VIRUS HIGHLY EXPRESSING HA PROTEIN AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20140227310
    Abstract: A PR8 recombinant influenza virus contains an HA and/or NA gene of H1, H3, H4, H5, H6, H7, H9 or H10 subtype influenza virus, and 6 internal genes (PB1, PB2, PA, NP, M and NS genes) of PR8 virus, in which the NS and/or NP gene have the following mutation sites: the NS2 protein encoded by the NS gene has an E67S point mutation, E74S point mutation, or E67S/E74S point mutation, and the NP protein encoded by the NP gene has a G132A point mutation.
    Type: Application
    Filed: September 4, 2012
    Publication date: August 14, 2014
    Applicant: SHANGHAI VETERINARY RESEARCH INSTITUTE, CAAS
    Inventors: Zejun Li, Qiaoyang Teng
  • INFECTIVITY-ENHANCED CONDITIONALLY-REPLICATIVE ADENOVIRUS AND USES THEREOF
    Publication number: 20140227226
    Abstract: A modified adenovirus capable of overcoming the problem of low level of coxsackie-adenovirus receptor (CAR) expression on tumor cells and methods of using such adenovirus are provided. The fiber protein of the adenovirus is modified by insertion or replacement so as to target the adenovirus to tumor cells, and the replication of the modified adenovirus is limited to tumor cells due to specific promoter control or mutations in E1a or E1b genes.
    Type: Application
    Filed: January 6, 2014
    Publication date: August 14, 2014
    Applicants: The UAB Research Foundation, The Board of Regents of the University of Texas System
    Inventors: Juan FUEYO-MARGARETO, Candelaria GOMEZ-MANZANO, David CURIEL
  • NON-ENTOMOPHILOUS TOMATO YELLOW LEAF CURL VIRUS
    Publication number: 20140227230
    Abstract: An object of the present invention is to provide a novel method of controlling TYLCV whereby the infection cycle of TYLCV can be broken. The present invention provides a novel virus that is not transmitted by an insect vector as a tomato yellow leaf curl virus. The present invention also provides a method of controlling a tomato yellow leaf curl disease and a method of preventing transmission of a yellow leaf curl virus by using a tomato yellow leaf curl virus not transmitted by an insect vector.
    Type: Application
    Filed: February 3, 2012
    Publication date: August 14, 2014
    Applicants: UTSUNOMIYA UNIVERSITY, KIKKOMAN CORPORATION
    Inventors: Hiroki Atarashi, Toshiro Inoue, Haruki Sayama, Hisashi Nishigawa, Tamotsu Murai, Tomohide Natsuaki
  • Protein and nucleic acid delivery vehicles, components and mechanisms thereof
    Patent number: 8802418
    Abstract: Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: August 12, 2014
    Assignee: The Catholic University of America
    Inventor: Venigalla B. Rao
  • Production of viruses, viral isolates and vaccines
    Patent number: 8802417
    Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: August 12, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Giuseppe Marzio, Maria Grazia Pau, Dirk Jan Elbertus Opstelten, Alphonsus Gerardus Cornelis Maria Uytdehaag
  • Herpes simplex virus mutant ICP0
    Patent number: 8802109
    Abstract: A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: August 12, 2014
    Assignees: University of Kansas, Southern Illinois University
    Inventors: David Davido, William Halford
  • IN VITRO MICROPHYSIOLOGICAL SYSTEM FOR HIGH THROUGHPUT 3D TISSUE ORGANIZATION AND BIOLOGICAL FUNCTION
    Publication number: 20140220555
    Abstract: Techniques for generating microtissues, including a micro-fabricated platform including at least one micro-well including a plurality of micro-cantilevers coupled thereto and surrounded by a plurality of ridges, each micro-cantilever including a cap at a terminal end thereof. The platform can be immersed in a suspension of cells. The suspension of cells can be driven into at least one micro-well, and the ridges can be de-wetted to remove excess suspension and isolate the suspension of cells in each micro-well. The cells can be driven in the suspension of each micro-well toward a top surface of the suspension, which can be polymerized to form a matrix. The cells can be cultivated to spontaneously compact the matrix such that the micro-cantilevers anchor and constrain the contracting matrix to form a band of microtissue that spans across the micro-cantilevers.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 7, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Christopher S. Chen, Ken Margulies, Thomas Boudou, Wesley Legant, Michael T. Yang
  • YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF
    Publication number: 20140220061
    Abstract: Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a Pichia pastoris strain and isolated using pressurized mechanical lysis. The disclosed VLPs can be used as immunogenic compositions for the prevention or treatment of flavivirus infection. Also described are isolated nucleic acid molecules encoding a flavivirus capsid (C) protein; a flavivirus premembrane (prM) protein; and at least one flavivirus envelope (E) protein or a flavivirus E protein lacking the transmembrane domain (E?TM), wherein the nucleic acid molecule further encodes at least one foot and mouth disease virus (FMDV) 2A autocatalytic site (2A) positioned between two flavivirus protein coding sequences. Expression of such nucleic acid molecules in a host cell produces flavivirus VLPs.
    Type: Application
    Filed: August 30, 2012
    Publication date: August 7, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Jared D. Evans, Nicole M. Beatty
  • PROCESS FOR THE PRODUCTION OF FILAMENTOUS BACTERIOPHAGE
    Publication number: 20140220660
    Abstract: The invention relates to culture conditions and methods that allow reproducible production of high titers of filamentous bacteriophage. Culture media comprising high titers of filamentous bacteriophage, as we methods of producing high titers of filamentous phage on a large scale are encompassed.
    Type: Application
    Filed: July 27, 2012
    Publication date: August 7, 2014
    Inventors: Jason Wright, Marc Bradford, Frank Sugar, Tim Davies, Kevin Millsap
  • THE METHOD OF OBTAINING A STRAIN OF BACTERIOFAGE, SPECIFIC STRAINS OF BACTERIOPHAGE AND USE THEREOF
    Publication number: 20140220659
    Abstract: A method for obtaining a strain of bacteriophage specific to a selected strain of bacteria was found as well as bacteriophage strains obtained in this way. Moreover, application of bacteriophages in manufacturing of the preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these phages was described.
    Type: Application
    Filed: August 9, 2012
    Publication date: August 7, 2014
    Applicant: PROTEON PHARMACEUTICALS S.A.
    Inventors: Jaroslaw Dastych, Jaroslaw Dziadek, Elzbieta Gorecka, Anna Rumijowska-Galewicz, Arkadiusz Wojtasik, Ewelina Wojcik
  • MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS
    Publication number: 20140220075
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: August 7, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Enrich HOFFMAN, Hong Jin, Bin Lu, Greg Duke, George Kemble
  • LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS
    Publication number: 20140220106
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: September 13, 2013
    Publication date: August 7, 2014
    Applicants: The Regents of the University of California, Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • BINDING MOLECULES FOR HUMAN FACTOR VIII AND FACTOR VIII-LIKE PROTEINS
    Publication number: 20140221611
    Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 7, 2014
    Applicant: DYAX CORP.
    Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
  • NOVEL SALMONELLA BACTERIOPHAGE COMPOSITIONS AND USES THEREOF
    Publication number: 20140219968
    Abstract: The present invention relates to novel bacteriophages and bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them, all of them belonging to the Caudovirales order. The novel bacteriophages and the bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them are Salmonella specific bacteriophages and have lytic activity against Salmonella.
    Type: Application
    Filed: July 27, 2012
    Publication date: August 7, 2014
    Applicant: UNIVERSITAT AUTONOMA DE BARCELONA
    Inventors: Montserrat Llagostera, Jorge Barbé, Carlota Bardina, Maria Pilar Cortés, Denis Augusto Spricigo
  • Stable, dried rotavirus vaccine, compositions and process for preparation thereof
    Patent number: 8795686
    Abstract: The present invention provides novel lyophilized rotavirus vaccine formulations and methods of their preparation. The formulations include vaccine stabilizers, resulting in a vaccine formulation with enhanced stability and minimal loss of potency. The rotavirus vaccine formulations comprise an advantageous ratio of a disaccharide (such as sucrose) to an amino acid (such as glycine). The lyophilization results in a virus formulation with 100% virus preservation and residual moisture from about 0.8% to 1.4%.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: August 5, 2014
    Assignee: Serum Institute of India
    Inventors: Rajeev M. Dhere, Sambhaji S. Pisal, Jagdish K. Zade
  • Agent for use in the topical or local treatment of cervical dysplasias
    Patent number: 8795684
    Abstract: The invention relates to an agent for treating cervical dysplasias, comprising a recombinant, genetically modified E1-deleted adenovirus replication defective in non-HPV infected cells, which is suitable for local external application in the region of the portio and the cervix uteri.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: August 5, 2014
    Assignee: Charite-Universitaetsmedizin Berlin
    Inventor: Guenter Cichon